Lupus Nephritis - Global Clinical Trials Review, 2026
Summary
The analyst's clinical trial report, “Lupus Nephritis - Global Clinical Trials Review, 2026" provides an overview of Lupus Nephritis Clinical trials scenario. This report provides top line data relating to the clinical trials on Lupus Nephritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The Clinical Trial Reports are generated using the analyst’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Table of Contents
- Report Guidance
- The Analyst Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Lupus Nephritis to Immunology Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Lupus Nephritis to Immunology Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Lupus Nephritis Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Lupus Nephritis
- Sep 28, 2026: Adicet Bio Announces Positive Safety and Efficacy Data From Prula-Cel (Formerly ADI-001) Study in Patients With SLE With or Without LN
- Sep 25, 2026: Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
- Sep 25, 2026: Adicet Bio to Host Webcast to Present Prula-cel Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
- Sep 09, 2026: Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
- Sep 09, 2026: Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-The-Shelf CAR T-Cell Product Candidate at the CCR - West 2026 Meeting
- Sep 03, 2026: Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
- Sep 01, 2026: Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of Prula-Cel (Formerly ADI-001) Study in SLE With or Without LN
- Aug 17, 2026: Fate Therapeutics begins Phase II trial of FT819 for lupus nephritis
- Aug 03, 2026: Akebia Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
- Jul 27, 2026: AbelZeta Receives FDA Clearance of Registrational Phase II Trial for C-CAR168 in Refractory Lupus Nephritis
- Jul 06, 2026: Fate to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
- Jul 06, 2026: Aurinia Announces Initiation of PRESERVE, a Study Investigating Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Lupus Nephritis
- Clinical Trial Profile Snapshots
- Appendix
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About the Analyst
- Contact Us
- Source
- Lupus Nephritis Therapeutics, Global, Clinical Trials by Region, 2026*
- Lupus Nephritis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Lupus Nephritis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Europe, Top Five Countries, 2026*
- Lupus Nephritis Therapeutics Clinical Trials, North America, Top Countries, 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2026*
- Proportion of Lupus Nephritis to Immunology Clinical Trials, G7 Countries (%), 2026*
- Lupus Nephritis Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Lupus Nephritis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Lupus Nephritis to Immunology Clinical Trials, E7 Countries (%), 2026*
- Lupus Nephritis Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Lupus Nephritis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Lupus Nephritis Therapeutics, Global, Clinical Trials by Phase, 2026*
- Lupus Nephritis Therapeutics, Global, Clinical Trials In Progress by Phase 2026*
- Lupus Nephritis Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Lupus Nephritis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- Lupus Nephritis Therapeutics, Global, Clinical Trials by Region (%), 2026*
- Lupus Nephritis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Lupus Nephritis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2026*
- Lupus Nephritis Therapeutics Clinical Trials, North America, Top Countries (%), 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2026*
- Proportion of Lupus Nephritis to Immunology Clinical Trials, G7 Countries (%), 2026*
- Lupus Nephritis Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Lupus Nephritis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Lupus Nephritis to Immunology Clinical Trials, E7 Countries (%), 2026*
- Lupus Nephritis Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Lupus Nephritis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Lupus Nephritis Therapeutics, Global, Clinical Trials by Phase (%), 2026*
- Lupus Nephritis Therapeutics, Global, Clinical Trials In Progress by Phase, 2026*
- Lupus Nephritis Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Lupus Nephritis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Lupus Nephritis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- The Analyst Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Roche Holding AG
- Aurinia Pharmaceuticals Inc
- Novartis AG
- Thermo Fisher Scientific Inc
- AstraZeneca Plc
- ICON Plc
- Bristol-Myers Squibb Co
- IQVIA Holdings Inc
- Labcorp Holdings Inc
- Otsuka Holdings Co Ltd
